ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Get Free Report) insider James Kihara sold 1,326 shares of ACADIA Pharmaceuticals stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $16.94, for a total value of $22,462.44. Following the completion of the sale, the insider now owns 14,370 shares of the company's stock, valued at approximately $243,427.80. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.
James Kihara also recently made the following trade(s):
- On Monday, April 8th, James Kihara sold 1,790 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $17.87, for a total transaction of $31,987.30.
- On Monday, February 26th, James Kihara sold 474 shares of ACADIA Pharmaceuticals stock. The stock was sold at an average price of $24.67, for a total value of $11,693.58.
ACADIA Pharmaceuticals Stock Performance
NASDAQ:ACAD opened at $17.05 on Friday. The stock has a market cap of $2.82 billion, a price-to-earnings ratio of -44.87 and a beta of 0.42. ACADIA Pharmaceuticals Inc. has a one year low of $16.16 and a one year high of $33.99. The business's 50-day simple moving average is $19.15 and its 200 day simple moving average is $23.33.
Elon to Transform U.S. Economy?
From Porter & Company | Ad
A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites.
And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.
One company holds a near-total monopoly on it.
ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last announced its earnings results on Tuesday, February 27th. The biopharmaceutical company reported $0.28 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.32 by ($0.04). ACADIA Pharmaceuticals had a negative net margin of 8.44% and a negative return on equity of 15.67%. The business had revenue of $231.04 million during the quarter, compared to analyst estimates of $223.79 million. During the same period in the previous year, the company earned ($0.26) earnings per share. The business's revenue for the quarter was up 69.3% on a year-over-year basis. On average, equities research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.62 EPS for the current year.
Institutional Inflows and Outflows
A number of large investors have recently added to or reduced their stakes in the stock. RTW Investments LP increased its position in shares of ACADIA Pharmaceuticals by 18.3% in the 3rd quarter. RTW Investments LP now owns 11,576,537 shares of the biopharmaceutical company's stock worth $241,255,000 after purchasing an additional 1,793,288 shares during the last quarter. Fred Alger Management LLC grew its stake in ACADIA Pharmaceuticals by 38.7% in the third quarter. Fred Alger Management LLC now owns 3,108,883 shares of the biopharmaceutical company's stock worth $64,789,000 after purchasing an additional 867,818 shares in the last quarter. First Trust Advisors LP increased its holdings in ACADIA Pharmaceuticals by 9.1% in the fourth quarter. First Trust Advisors LP now owns 1,777,307 shares of the biopharmaceutical company's stock valued at $55,647,000 after buying an additional 148,526 shares during the last quarter. Emerald Advisers LLC raised its stake in ACADIA Pharmaceuticals by 4.0% during the third quarter. Emerald Advisers LLC now owns 1,681,052 shares of the biopharmaceutical company's stock valued at $35,033,000 after buying an additional 64,100 shares in the last quarter. Finally, Norges Bank bought a new position in ACADIA Pharmaceuticals during the 4th quarter worth approximately $45,187,000. 96.71% of the stock is currently owned by institutional investors.
Analysts Set New Price Targets
ACAD has been the subject of several research analyst reports. Cantor Fitzgerald restated an "overweight" rating and set a $37.00 price target on shares of ACADIA Pharmaceuticals in a research note on Tuesday. JPMorgan Chase & Co. cut their price target on shares of ACADIA Pharmaceuticals from $29.00 to $25.00 and set an "overweight" rating on the stock in a report on Monday, March 25th. StockNews.com upgraded shares of ACADIA Pharmaceuticals from a "hold" rating to a "buy" rating in a research note on Tuesday, January 30th. Royal Bank of Canada reduced their target price on shares of ACADIA Pharmaceuticals from $36.00 to $35.00 and set an "outperform" rating on the stock in a report on Wednesday, February 28th. Finally, JMP Securities reaffirmed a "market outperform" rating and set a $42.00 price target on shares of ACADIA Pharmaceuticals in a research report on Wednesday, February 7th. Three analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average target price of $32.13.
Get Our Latest Stock Report on ACAD
ACADIA Pharmaceuticals Company Profile
(
Get Free Report)
ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. This story was reviewed by InsiderTrades.com's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
